By David Wang, Masha Hoffey and Dr Simone Sharma

This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or ...

By Dr Alexander C. Maue

It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducib...

By Helen Stewart-Miller and Dr Kate Tointon

Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, i...

By Dr Mark Roberts and Dr Sam Genway

AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predi...

By Dr Richard M. Eglen

In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in ...

By Dr Steve Arlington and John Wise

One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look...

By Dr Philip S. Jones and Dr Stuart P. McElroy

While the quality of the compound collection is frequently described as a key determinant of the success of a high throughput screening campaign, i...

By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this pr...